These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34791974)
1. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. Udayachalerm S; Renouard MG; Anothaisintawee T; Thakkinstian A; Veettil SK; Chaiyakunapruk N J Med Econ; 2022; 25(1):26-37. PubMed ID: 34791974 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401 [TBL] [Abstract][Full Text] [Related]
4. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Giannelos N; Ng C; Curran D Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240 [TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447 [TBL] [Abstract][Full Text] [Related]
7. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218 [TBL] [Abstract][Full Text] [Related]
8. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025 [TBL] [Abstract][Full Text] [Related]
9. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Mbinta JF; Nguyen BP; Awuni PMA; Paynter J; Simpson CR Lancet Healthy Longev; 2022 Apr; 3(4):e263-e275. PubMed ID: 36098300 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145 [TBL] [Abstract][Full Text] [Related]
11. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Xia Y; Zhang X; Zhang L; Fu C Front Immunol; 2022; 13():978203. PubMed ID: 36248796 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691 [TBL] [Abstract][Full Text] [Related]
14. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Oh H; Tan C; Williams C; Giannelos N; Ng C Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600 [TBL] [Abstract][Full Text] [Related]
15. The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study. Kim S; Choi JK; Suh J; Park SH; Lee J Vaccine; 2024 Jul; 42(19):4046-4055. PubMed ID: 38762358 [TBL] [Abstract][Full Text] [Related]
16. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review. Meredith NR; Armstrong EP Prev Med Rep; 2022 Oct; 29():101923. PubMed ID: 35898193 [TBL] [Abstract][Full Text] [Related]
18. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027 [TBL] [Abstract][Full Text] [Related]
19. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years. Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]